Related Experiment Video
Updated: May 22, 2025
Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing
Published on: September 25, 2011
Expression Profiles of Five Common Cancer Membrane Protein Antigens Collected for the Development of Cocktail CAR-T
Tetsuya Nakatsura1, Kazumasa Takenouchi1, Jun Kataoka1
1Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa 277-8577, Japan.
Abstract:
Although CD19 CAR-T has been highly effective against B-cell blood cancers, there are few reports of successful treatments for solid cancers, probably because there are few protein antigens specifically expressed on the surface of the cancer cell membrane. The key to developing a groundbreaking CAR-T cell therapy effective against solid cancers is to "overcome the heterogeneity of cancer antigens". For this purpose, it is necessary to target multiple cancer antigens simultaneously. In this study, we performed immunohistochemical analysis of various solid cancer specimens using antibodies against ROBO1, EphB4, CLDN1, and LAT1 in addition to GPC3, which we have previously studied. These antigens were frequently expressed in various solid cancers but shown to be rarely expressed, with some exceptions, in non-cancerous normal organs adjacent to the cancer. Although ROBO1 and GPC3 are often expressed in cytoplasm, there are also cases in which they are expressed on the cell membrane depending on the type of cancer. On the other hand, it has been revealed that three antigens-EphB4, CLDN1, and LAT1-are frequently expressed only on the cell membrane of cancer cells in various solid cancers, suggesting that they may be ideal targets for CAR-T cell therapy.
Insights
Targeting multiple cancer antigens is key for effective CAR-T cell therapy against solid tumors. Researchers identified EphB4, CLDN1, and LAT1 as promising cell surface targets for solid cancer treatment.
Area of Science:
- Oncology
- Immunotherapy
- Cancer Research
Background:
- Chimeric antigen receptor T-cell (CAR-T) therapy shows success in blood cancers but faces challenges in solid tumors.
- Limited availability of specific cancer cell surface antigens hinders solid tumor CAR-T development.
- Overcoming cancer antigen heterogeneity is crucial for advancing CAR-T therapies for solid malignancies.
Purpose of the Study:
- To identify novel, specific cell surface antigens for CAR-T therapy in solid cancers.
- To evaluate the expression patterns of ROBO1, EphB4, CLDN1, and LAT1 in various solid tumors.
- To determine the suitability of these antigens as targets for CAR-T cell therapy.
Main Methods:
- Immunohistochemical analysis of diverse solid cancer tissue specimens.
- Utilized antibodies against ROBO1, EphB4, CLDN1, LAT1, and previously studied GPC3.
- Compared antigen expression in cancer tissues versus adjacent non-cancerous normal organs.
Main Results:
- ROBO1 and GPC3 showed variable expression, including cytoplasmic and cell membrane localization depending on cancer type.
- EphB4, CLDN1, and LAT1 were frequently detected on the cell membrane of various solid cancer cells.
- These three antigens exhibited minimal expression in adjacent normal tissues, indicating specificity.
Conclusions:
- EphB4, CLDN1, and LAT1 are frequently expressed on the cell membrane of diverse solid cancers.
- These antigens represent promising and specific targets for developing novel CAR-T cell therapies for solid tumors.
- Targeting multiple antigens like EphB4, CLDN1, and LAT1 may overcome heterogeneity challenges in solid cancer treatment.
More Related Videos
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
10:46A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
Published on: September 13, 2022
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...